

Press Release

Appointment of a New CSO Completes the Management Board of the medac Group

The Management Board of the medac Group is now complete. Dr Christoph Willers assumes responsibility for Research, Development and the Pipeline as Chief Scientific Officer (CSO)

Wedel, Germany, February 25, 2026 - With the appointment of Dr Christoph Willers as Chief Scientific Officer (CSO), the Management Board of the medac Group has been fully established. Science and Development are being further strengthened as a strategic dimension of corporate leadership, underscoring the scientific foundation and innovative strength of medac

Clear responsibility for Research, Development and the Pipeline

As CSO, Dr Willers is responsible for Research, Preclinical and Clinical Development, Clinical Studies, as well as Pipeline and Portfolio Management. His mandate is to consistently align research and development with medical needs while further strengthening scientific excellence.

"Scientific quality and clear priorities in research and development are essential for the continued advancement of our company. With Dr Willers, we are strengthening this dimension at Board level as well," says Frank Lucaßen, CEO of the medac Group

Advancing science and innovation

The CSO role also provides new momentum for the continued development of medac's scientific foundation. Alongside the ongoing optimisation of existing therapies, there will be an increased focus on new scientific approaches, evidence-based advancements and clinical research. The objective is to drive innovation where it delivers clear medical benefit.

Experience in building and transforming organisations

Dr Willers brings many years of experience in leading scientific organisations, as well as in building and transforming development and manufacturing capabilities. His combination of medical training, scientific expertise and leadership experience provides new perspectives for innovation and responsible development.

Media Contact
T +49 4103 8006 -9111
F +49 4103 8006 -8934
press@medac.de

medac Gesellschaft
für klinische
Spezialpräparate m.b.H

Theaterstraße 6
22880 Wedel
Germany
medac-group.com

With this appointment, medac continues to strengthen its scientific expertise. Step by step, and with the clear ambition of making medically necessary therapies available and improving the quality of life of patients worldwide.

About medac

At medac group, we believe that health is humanity's most valuable resource. Since 1970, our mission has been to improve patients' quality of life worldwide by making the best medical treatments available. As a globally operating pharmaceutical company headquartered in Germany, we provide high-quality medical treatments for patients worldwide in over 90 countries. With more than 2.000 employees we are committed to improving human health.

Our products are manufactured in Germany and other European countries to the highest standards, utilizing our own logistics center and production sites, and subsequently distributed worldwide.

We are constantly working to improve authorized medicines and to develop innovative therapies in the fields of rheumatology, urology, hematology, and oncology. Part of our mission is to provide safe, high-quality and innovative original products, as well as generics and biosimilars. In this way, we make vital treatments accessible to those affected.

Further information on the company can be found online at www.medac-group.com